MENRIUM 10-4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
| Metabolism | Chlordiazepoxide: Hepatic metabolism via CYP3A4 to active metabolites (desmethylchlordiazepoxide, demoxepam). Clidinium: Hepatic metabolism (primary pathway unclear). |
| Excretion | Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites) |
| Half-life | Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days. |
| Protein binding | Chlordiazepoxide: 96-98% bound to albumin. Clidinium: ~80% bound. |
| Volume of Distribution | Chlordiazepoxide: 0.3-0.5 L/kg; clidinium: 1.2-1.7 L/kg. Moderate tissue distribution. |
| Bioavailability | Oral: 100% (chlordiazepoxide); clidinium: 10-30% (extensive first-pass metabolism). |
| Onset of Action | Oral: 30-60 min (anxiolytic); 15-30 min (antispasmodic). |
| Duration of Action | 4-6 h (clinical effect); 24-48 h (residual sedation due to active metabolite nordiazepam). |
| Molecular Weight | Valproate: 144.21 Da; Chlordiazepoxide: 299.75 Da. (Combination product; individual molecular weights provided.) |
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Use with caution in renal impairment. GFR ≥10 mL/min: no adjustment; GFR <10 mL/min: avoid due to risk of accumulation of chlordiazepoxide metabolites. Not recommended in end-stage renal disease. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated due to impaired clearance. |
| Pediatric use | Not recommended for use in children. Safety and efficacy not established. For patients under 12 years, avoid use. |
| Geriatric use | Elderly patients are more sensitive to CNS effects. Initial dose: 1 tablet (5 mg chlordiazepoxide / 2.5 mg clidinium) twice daily; titrate slowly. Avoid doses >2 tablets per day. Monitor for sedation and anticholinergic side effects. |
| 1st trimester | Contraindicated due to risk of teratogenicity (neural tube defects, cardiovascular malformations) from valproate component; avoid unless no alternative and discuss risks. |
| 2nd trimester | Contraindicated due to valproate teratogenicity and potential developmental toxicity; avoid. |
| 3rd trimester | Contraindicated due to valproate teratogenicity and risk of neonatal hemorrhage, hepatic toxicity, and withdrawal syndrome; avoid. |
Clinical note
Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).
| Placental transfer | Both valproate and chlordiazepoxide cross the placenta; valproate reaches fetal levels similar to maternal, chlordiazepoxide and its active metabolites cross readily. |
| Breastfeeding | Valproate and chlordiazepoxide are excreted into breast milk. Valproate levels in milk are low but may cause infant hepatotoxicity; chlordiazepoxide may cause sedation, poor feeding, and weight loss. Use only if benefit outweighs risk, monitor infant for adverse effects. |
■ FDA Black Box Warning
Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for use in patients for whom alternative treatment options are inadequate.
| Serious Effects |
Hypersensitivity to valproate, chlordiazepoxide, or any componentSevere hepatic impairmentKnown mitochondrial polymerase gamma (POLG) disordersPorphyriaNarrow-angle glaucoma (due to anticholinergic effects of chlordiazepoxide)Concurrent use with delavirdine (valproate contraindication)Pregnancy (especially first trimester) due to teratogenicityBreastfeeding (relative contraindication, but often avoided)
| Precautions | Dependence and withdrawal reactions with prolonged use, Abuse potential, CNS depressant effects; caution with other CNS depressants, Paradoxical reactions (restlessness, agitation), Elderly patients more sensitive to anticholinergic effects (constipation, urinary retention, blurred vision), Impaired renal function may require dose adjustment |
| Food/Dietary | Avoid alcohol; avoid caffeine if it exacerbates gastrointestinal symptoms. No specific food restrictions, but a low-fiber diet may be recommended if used for gastrointestinal disorders. Grapefruit juice may potentially alter chlordiazepoxide metabolism (though not well documented for this combination); caution is advised. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, particularly cleft palate and neural tube defects, due to chlordiazepoxide. Second and third trimesters: Risk of neonatal withdrawal, respiratory depression, hypotonia, and sedation. Benzodiazepines are associated with floppy infant syndrome and dependence. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and CNS status. Fetal growth assessment and ultrasound for anomalies. Neonatal monitoring for withdrawal symptoms, respiratory depression, and hypotonia. |
| Fertility Effects | No specific human data on fertility. In animal studies, chlordiazepoxide may affect reproductive cycles and fertility at high doses. Clinical significance unknown. |
| Clinical Pearls | Menrium 10-4 contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg. Chlordiazepoxide is a benzodiazepine with anxiolytic and sedative properties; clidinium is an anticholinergic that reduces gastrointestinal motility and secretion. Use cautiously in elderly due to increased sensitivity to anticholinergic effects (confusion, constipation, urinary retention) and benzodiazepine sedation. Avoid in patients with narrow-angle glaucoma, myasthenia gravis, or severe hepatic impairment. Monitor for CNS depression when combined with alcohol or other sedatives. Abrupt discontinuation may precipitate benzodiazepine withdrawal symptoms. |
| Patient Advice | May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how this medication affects you. · Avoid alcohol and other sedatives (e.g., sleeping pills, muscle relaxants) as they can increase drowsiness and risk of severe side effects. · Do not stop taking suddenly without consulting your doctor, as withdrawal symptoms (anxiety, insomnia, irritability) may occur. · Report any eye pain, vision changes, difficulty urinating, or severe constipation to your healthcare provider. · This medication may cause dry mouth; sugarless gum or hard candy can help. If dry mouth persists, consult your dentist. |